查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016960

动物用药品市场：2026-2032年全球市场预测（产品类型、给药途径、目标动物及通路划分）

Veterinary Drug Market by Product Category, Route Of Administration, Animal Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物用药品市场价值将达到 487.2 亿美元，到 2026 年将成长至 518.4 亿美元，到 2032 年将达到 782.8 亿美元，复合年增长率为 7.00%。

主要市场统计数据
基准年 2025 487.2亿美元
预计年份：2026年 518.4亿美元
预测年份 2032 782.8亿美元
复合年增长率 (%) 7.00%

在不断变化的兽医保健格局中采取策略性行动：重点关注临床、商业性和监管因素，这些因素要求产业采取果断行动

现代动物用药品产业正处于加速创新、日益严格的监管以及终端用户需求不断变化这三者交汇的阶段。近年来，该行业的护理方法发生了演变，更加重视预防医学、生物製药以及更合理的抗生素使用。这些趋势正在改变供应商和兽医的行为，并促使投资在不同治疗领域和剂型之间重新分配。

科学、监管和商业领域的重大变化正在重塑动物用药品的优先事项，并重新定义如何为临床医生和饲主提供价值。

这些变革性的变化正在推动动物用药品产业研发重点、製造地和经营模式的重组。随着生物製药和新一代疫苗的兴起，人们对合理使用抗菌药物的关注度再次提升，促使研发公司致力于开发窄频谱药物、替代疗法以及用于指导治疗的先进诊断工具。同时，供应链韧性、灵活的生产结构以及合约研发生产（CDMO）伙伴关係等营运转型也在稳步推进，并逐渐成为核心能力。

2025 年不断增加的关税压力促使供应链进行全面重新设计，製造地按地区转移，筹资策略，以保障产品供应和获利能力。

2025年实施的关税调整进一步增加了采购、定价和跨境物流的复杂性，影响了产品供应和筹资策略。製造商和经销商正在重新审视与供应商的合约以及运输路线，以降低不断上涨的收货成本，并在不影响供货的前提下维持利润率。这些调整通常需要优先考虑短期库存，并实现长期供应来源多元化，以降低集中采购带来的风险。

从详细的细分观点，产品类型的交集揭示了差异化的机会。

精细的市场区隔技术清楚地揭示了治疗需求与分销复杂性之间的交汇点。依产品类型分析，市场包括感染疾病物、抗发炎药物、驱虫药和疫苗。感染疾病物包括抗生素、抗真菌药物和抗病毒药物，其中抗生素细分为头孢菌素类、Fluoroquinolones、大环内酯类、青霉素类和四环霉素。这种细緻的分类揭示了不同的创新路径和合理用药考量，这些因素会影响研发重点和标籤策略。

美洲、欧洲、中东和非洲以及亚太地区的战略考量表明，每个地区的采用率、监管要求和分销挑战各不相同。

区域趋势对有效的商业和监管策略至关重要。美洲市场的特点是拥有先进的兽医临床基础设施、宠物拥有率高，以及对高品质生技药品和诊断试剂日益增长的需求。这些特点有利于强劲的创新和新疗法的早期上市。由于不同地区的政策和支付模式存在差异，因此在市场准入和报销谈判中需要采取细緻入微、因地制宜的方法。

为了在兽医市场中超越竞争对手，竞争策略正在形成，其核心是综合治疗方法、数位服务、强大的供应链和证据生成。

随着成熟的跨国动物用药品公司不断拓展产品线，竞争格局正在发生变化，专注于生技药品、诊断和新型驱虫药的敏捷型专业公司应运而生。主要企业优先考虑整合治疗方案，将治疗药物与数位支援工具、疗效追踪以及能够增强兽医和饲主互动体验的服务相结合。策略合作和授权协议正被越来越多地用于加速新治疗方法的推广应用，并分散生技药品和专科疗法相关的研发风险。

为了确保可持续的竞争优势，经营团队必须采取切实可行的策略行动，将合理使用抗菌药物、区域生产和以通路为中心的商业化连结起来。

产业领导企业应优先采取一系列切实可行的措施，协调科学、供应和行销，在掌握短期机会的同时，建构长期韧性。首先，推动合理抗菌药物使用（AMS）工作，并配合标靶药物药物和诊断药物的研发，能够满足不断变化的监管要求和临床医生对更安全、循证治疗方法的需求。其次，投资建立灵活的生产结构和区域生产能力，特别是针对关键生物製药和疫苗，可以降低关税和物流风险，并提高市场应对力。

采用严谨的混合方法研究途径，结合关键相关人员的访谈、二手资讯和情境分析，来检验趋势和策略意义。

本调查方法结合了定量和定性方法，以确保获得可靠且可操作的洞见。第一阶段包括对价值链上的关键相关人员进行结构化访谈，这些利益相关者包括临床医生、采购负责人和行业高管，旨在了解他们对临床需求、处方集决定因素和分销偏好的真实观点。第二阶段则利用监管文件、临床文献、专利申请和企业资讯披露来佐证趋势并确定新兴技术的部署路径。

这项具有前瞻性的综合分析概述了科学、营运和商业性策略的整合将如何决定兽医治疗领域的长期成功。

总之，在科学创新、法规演变和商业性格局变化的驱动下，动物用药品产业正经历一场意义深远的变革时期。积极实践合理使用抗菌药物原则、投资建立稳健灵活的生产系统，并针对不同动物群体和分销管道的独特需求优化商业性策略的利益相关者，将更有利于获得长期价值。区域相关人员仍然至关重要。美洲、欧洲、中东、非洲和亚太地区各自拥有独特的监管、临床和物流现实，在製定市场准入和扩大策略时必须认真考虑这些因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：动物用药品市场：依产品类型

  • 抗感染药物
    • 抗生素
      • 头孢菌素
      • Fluoroquinolones
      • 大环内酯类
      • 青霉素
      • 四环霉素
    • 抗真菌药物
    • 抗病毒药物
  • 抗发炎药
  • 杀虫剂
  • 疫苗

第九章：动物用药品市场：依给药途径划分

  • 吸入
  • 注射药物
  • 口服
  • 外用

第十章：动物用药品市场：依目标动物划分

  • 水产养殖
    • 鱼
    • 虾
  • 伴侣动物
    • 狗
    • 猫
  • 马
  • 家畜
    • 牛
    • 小反刍动物
    • 猪
  • 家禽
    • 鸡
    • 火鸡

第十一章：动物用药品市场：依通路划分

  • 网路药房
  • 零售药房
  • 动物医院

第十二章：动物用药品市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：动物用药品市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章动物用药品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国：动物用药品市场

第十六章 中国：动物用药品市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-034B50030391

The Veterinary Drug Market was valued at USD 48.72 billion in 2025 and is projected to grow to USD 51.84 billion in 2026, with a CAGR of 7.00%, reaching USD 78.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.72 billion
Estimated Year [2026] USD 51.84 billion
Forecast Year [2032] USD 78.28 billion
CAGR (%) 7.00%

A strategic introduction to the evolving veterinary therapeutics environment highlighting clinical, commercial, and regulatory forces that demand decisive industry responses

The contemporary veterinary drug landscape sits at the intersection of accelerating innovation, heightened regulatory scrutiny, and shifting end-user expectations. In recent years the industry has seen evolving modes of care that emphasize preventive health, biologics, and more nuanced antimicrobial stewardship. These dynamics are reshaping supplier and practitioner behavior, driving a rebalancing of investment across therapeutic classes and delivery formats.

As stakeholders adapt, the need for a clear strategic foundation becomes paramount. Veterinarians and industry leaders are navigating pressures from tighter regulations on antimicrobial use, rising demand for safer and more targeted therapies, and the operational realities of delivering care across diverse animal species and care settings. Moreover, the adoption of digital channels and telehealth has begun to influence how products are distributed and how owners access treatment options. Consequently, market participants must reassess portfolio priorities, manufacturing resilience, and engagement models with clinical end users to remain competitive.

Transitioning from observation to strategy requires synthesizing clinical trends with commercial realities. This introduction frames the essential forces shaping the field and sets the stage for deeper analysis on transformative shifts, tariff impacts, segmentation-driven opportunities, regional dynamics, competitive positioning, and practical recommendations for leaders seeking to translate insight into action.

High-impact scientific, regulatory, and commercial transformations are reshaping priorities in veterinary therapeutics and redefining how value is delivered to clinicians and owners

Transformative shifts are driving a reconfiguration of R&D priorities, manufacturing footprints, and commercial models within veterinary pharmaceuticals. The push toward biologics and next-generation vaccines has been accompanied by renewed attention to antimicrobial stewardship, prompting developers to pursue narrower-spectrum agents, alternative modalities, and enhanced diagnostic tools to guide therapy. These scientific trends are paralleled by operational transformations: supply chain resilience, flexible manufacturing, and the adoption of contract development and manufacturing partnerships are becoming core capabilities.

Commercially, channel dynamics are evolving as online pharmacies and digital platforms expand access while traditional veterinary hospitals remain central for clinical interventions. This digitization, combined with improved data capture at point of care, creates opportunities for outcomes-focused offerings and subscription-based preventative programs. Shifts in animal ownership patterns-such as higher investment in companion animal health-are altering demand mix across therapeutic categories and routes of administration, influencing formulary decisions and promotional strategies.

Regulatory frameworks and payer expectations are tightening, which compels companies to design evidence generation plans that demonstrate safety, efficacy, and real-world value. Collectively, these shifts require organizations to adopt integrated strategies that align scientific innovation with supply chain agility and commercial modernization to capture sustainable advantage.

Elevated tariff pressures in 2025 are prompting comprehensive supply chain redesigns, regional manufacturing shifts, and procurement strategies to safeguard access and margins

Tariff changes implemented in 2025 have introduced additional layers of complexity for sourcing, pricing, and cross-border logistics, affecting product availability and procurement strategies. Manufacturers and distributors are reassessing supplier contracts and transportation routes to mitigate increased landed costs and to preserve margins without compromising accessibility. These adjustments often necessitate near-term inventory prioritization and long-term supply base diversification to reduce exposure to concentrated sourcing risks.

In practice, the tariff environment has accelerated conversations around regional manufacturing and onshoring for critical inputs and finished products, particularly for essential classes such as anti-infectives and vaccines. Companies are also revisiting transfer pricing frameworks and distribution agreements to manage costs across geographies. For clinical stakeholders, the outcome is a heightened focus on formulary rationalization and therapeutic substitution where feasible, underpinned by a renewed emphasis on cost-effective, evidence-based therapy selection.

Looking ahead, tariffs are likely to remain a structural consideration in commercial planning, influencing decisions about where to invest in capacity, which partnerships to prioritize, and how to structure distribution networks to balance resilience with competitive pricing.

Deep segmentation perspectives reveal where product categories, administration routes, animal types, and distribution channels converge to create differentiated opportunities

A refined segmentation approach offers clarity on where therapeutic demand and distribution complexity converge. When analyzed by product category, the market encompasses anti-infectives, anti-inflammatories, parasiticides, and vaccines; within anti-infectives there are antibiotics, antifungals, and antivirals, and antibiotics can be further differentiated into cephalosporins, fluoroquinolones, macrolides, penicillins, and tetracyclines. This granularity reveals diverging innovation pathways and stewardship considerations that influence development priorities and labeling strategies.

Route of administration also shapes clinical adoption and commercial logistics, with inhalation, injectable, oral, and topical formats each presenting distinct formulation, storage, and administration constraints. Animal type segmentation shows differentiated demand drivers: aquaculture-comprising fish and shrimp-presents disease profiles and delivery challenges unlike those in companion animals, which include canines and felines; equine care emphasizes specialized therapeutics and dosing regimens; livestock, spanning cattle, small ruminants, and swine, requires scalable, cost-sensitive solutions; and poultry, represented by chickens and turkeys, demands approaches suited to mass administration and biosecurity.

Distribution channels further affect market access, where online pharmacies, retail pharmacies, and veterinary hospitals each offer unique customer touchpoints and compliance requirements. Synthesizing these segmentation lenses helps identify where product differentiation, targeted evidence, and tailored commercial models will deliver the greatest strategic return.

Regional strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific reveal differentiated adoption, regulatory, and distribution imperatives

Regional dynamics are central to effective commercial and regulatory strategy. In the Americas, markets are characterized by advanced veterinary clinical infrastructure, high companion animal ownership, and growing demand for premium biologics and diagnostics; these features support robust innovation and early adoption of novel therapeutics. Policies and payer models vary across the region, requiring nuanced approaches to market entry and reimbursement discussions.

Europe, Middle East & Africa present a heterogeneous landscape where stringent regulatory expectations in some markets coexist with emerging access challenges in others. Antimicrobial stewardship frameworks and harmonized safety standards are prominent in parts of Europe, while key growth opportunities may be found in markets with rising livestock intensity and expanding veterinary services. Meanwhile, supply chain considerations and import regulations in this region influence where localized manufacturing or distribution partnerships are most beneficial.

Asia-Pacific exhibits diverse demand drivers, from intensifying aquaculture production and large-scale livestock operations to rapidly expanding companion animal care in urban centers. Regulatory modernization, investments in cold chain infrastructure, and increasing digital adoption are reshaping how products are commercialized. Together, these regional insights suggest that tailored regulatory strategies, differentiated product positioning, and adaptive distribution models are essential for successful market penetration and sustainable growth.

Competitive strategies are coalescing around integrated therapeutics, digital services, resilient supply chains, and evidence generation to outpace peers in veterinary markets

Competitive positioning is evolving as incumbent multinational animal health companies expand their portfolios alongside nimble specialized players focused on biologics, diagnostics, and novel antiparasitic agents. Leading firms are prioritizing integrated solutions that combine therapeutics with digital support tools, outcomes tracking, and services that enhance veterinarian and owner engagement. Strategic collaborations and licensing agreements are increasingly used to accelerate access to novel modalities and to spread the development risk associated with biologics and specialty therapeutics.

Operational excellence remains a differentiator: companies that have invested in flexible manufacturing, robust quality systems, and resilient supply chains are better positioned to navigate tariff volatility and fluctuating demand across animal types. Equally important is the ability to generate and communicate high-quality clinical evidence that resonates with both regulatory bodies and practitioners. As the competitive landscape matures, firms that align product innovation with accessible delivery formats and compelling value propositions will secure advantage in both clinical preference and procurement decisions.

Practical strategic actions for leadership to synchronize antimicrobial stewardship, regional manufacturing, and channel-focused commercialization for sustained advantage

Industry leaders should prioritize a set of actionable moves that align science, supply, and sales to capture near-term opportunities while building long-term resilience. First, advancing antimicrobial stewardship initiatives alongside development of targeted agents and diagnostics will meet evolving regulatory expectations and clinician demand for safer, evidence-based therapies. Second, investing in flexible manufacturing and regional capacity-especially for critical biologics and vaccines-will mitigate tariff and logistics exposure and accelerate market responsiveness.

Commercially, tailoring offerings by combining therapeutics with digital adherence tools and practice-level support will strengthen relationships with veterinary hospitals and differentiate products sold through online and retail pharmacies. Segment-focused strategies should recognize that companion animal owners prioritize convenience and advanced care, whereas livestock and poultry customers emphasize affordability, ease of administration, and scalability. Finally, leaders should adopt agile pricing and distribution models informed by regional regulatory landscapes and local channel economics to maintain competitiveness while preserving clinical choice.

A rigorous mixed-methods research approach combining primary stakeholder interviews, secondary intelligence, and scenario analysis to validate trends and strategic implications

The research methodology blends quantitative and qualitative approaches to ensure robust, actionable findings. Primary research involved structured interviews with key stakeholders across the value chain, including clinical practitioners, procurement specialists, and industry executives, to capture real-world perspectives on clinical needs, formulary drivers, and distribution preferences. Secondary research incorporated regulatory documents, clinical literature, patent filings, and company disclosures to corroborate trends and identify emerging technology pathways.

Analytical frameworks applied include segmentation analysis across product categories, routes of administration, animal types, and distribution channels to reveal demand patterns and operational constraints. Scenario analysis was used to stress-test supply chain and tariff sensitivities, while cross-regional comparisons illuminated regulatory and commercial variances. Data quality controls and triangulation methods were employed throughout to validate insights, and findings were peer-reviewed by subject matter experts with clinical and commercial experience in veterinary therapeutics.

A forward-looking synthesis outlining how integrated scientific, operational, and commercial strategies will determine long-term success in veterinary therapeutics

In conclusion, the veterinary drug landscape is undergoing a period of substantive change driven by scientific innovation, regulatory evolution, and shifting commercial dynamics. Stakeholders who proactively integrate antimicrobial stewardship principles, invest in resilient and flexible manufacturing, and tailor commercial approaches to the unique needs of each animal segment and distribution channel will be best positioned to capture long-term value. Regional nuance remains a decisive factor: the Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct regulatory, clinical, and logistical realities that must inform market entry and expansion strategies.

Ultimately, the most successful organizations will be those that translate insight into coordinated execution-aligning R&D priorities with practical deployment plans, building partnerships that accelerate access to novel modalities, and deploying commercial models that resonate with practitioners and owners. This synthesis of clinical credibility, operational strength, and commercial agility defines the pathway to sustainable success in the evolving veterinary therapeutics arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Drug Market, by Product Category

  • 8.1. Anti-Infectives
    • 8.1.1. Antibiotics
      • 8.1.1.1. Cephalosporins
      • 8.1.1.2. Fluoroquinolones
      • 8.1.1.3. Macrolides
      • 8.1.1.4. Penicillins
      • 8.1.1.5. Tetracyclines
    • 8.1.2. Antifungals
    • 8.1.3. Antivirals
  • 8.2. Anti-Inflammatories
  • 8.3. Parasiticides
  • 8.4. Vaccines

9. Veterinary Drug Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Veterinary Drug Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shrimp
  • 10.2. Companion Animals
    • 10.2.1. Canines
    • 10.2.2. Felines
  • 10.3. Equine
  • 10.4. Livestock
    • 10.4.1. Cattle
    • 10.4.2. Small Ruminants
    • 10.4.3. Swine
  • 10.5. Poultry
    • 10.5.1. Chickens
    • 10.5.2. Turkeys

11. Veterinary Drug Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Hospitals

12. Veterinary Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Veterinary Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Veterinary Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Veterinary Drug Market

16. China Veterinary Drug Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Boehringer Ingelheim International GmbH
  • 17.6. Ceva Sante Animale S.A.
  • 17.7. Dechra Pharmaceuticals PLC
  • 17.8. Elanco Animal Health Incorporated
  • 17.9. Merck & Co., Inc.
  • 17.10. Norbrook Laboratories Limited
  • 17.11. Phibro Animal Health Corporation
  • 17.12. Vetoquinol S.A.
  • 17.13. Virbac S.A.
  • 17.14. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GCC VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 215. GCC VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. GCC VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 221. GCC VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. G7 VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. G7 VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 254. G7 VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. NATO VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 259. NATO VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 265. NATO VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)